Shares of Tesaro Inc. fell after the U.S. FDA denied the company’s New Drug Application for rolapitant IV, an injectable form of its oral treatment Varubi.

Tesaro Inc. data showed the oral, once-daily PARP inhibitor niraparib could benefit 70% of all ovarian cancer patients who received previous chemo treatments.

Clovis Oncology shares jumped more than 15 percent after the FDA opted to not hold an advisory committee meeting to discuss the company’s application for its ovarian cancer drug rucaparib.

Cancer researchers are just beginning to understand the ramifications of the fundamental discoveries behind the 2015 Nobel Prizes in Chemistry, which were awarded on Wednesday to three scientists for explaining how cells repair mistakes in DNA that occur when cells divide. When deoxyribonucleic acid (DNA) repair mechanisms fail, they predispose people to cancer. That is […]

Talazoparib Is a Highly-Potent PARP Inhibitor in Phase 3 Development for the Treatment of BRCA-Mutated Breast Cancer; Clinical Activity Observed in Multiple Oncology Opportunities With Potential for Monotherapy or Combination Therapy With Standard of Care Oncology Treatments; Transaction Price of $410 Million Upfront, Up to $160 Million in Milestones and Mid-Single Digit Royalties SAN FRANCISCO, […]

San Francisco-based Medivation, Inc. (MDVN), and San Rafael, Calif.-based BioMarin Pharmaceutical Inc. (BMRN) announced today that they have signed a deal for Medivation to buy all worldwide rights to talazoparib, formerly called BMN 673, for breast cancer treatment. Medivation will take over all research, development, regulatory and commercial activities.   Medivation will pay BioMarin $410 […]